Leerink Comments On Orexigen Therapeutics, Says Current Projections Could Prove To Be 'Conservative'

In a report published Wednesday, Leerink analyst Paul Matteis commented on Orexigen Therapeutics, Inc. OREX and wrote that following a positive opinion from the CHMP, the company expects a final opinion from the EMA on the Mysimba (Contrave) marketing authorization application. Matteis noted that he expects peak ex-US risk-adjusted Mysimba revenues of $50 million in 2025 which could yield $15 million in royalties for Orexigen Therapeutics. The analyst also added that the company is currently in discussions with potential ex-U.S. partners, and a collaboration agreement that has a large European Union and Rest of World footprint could render current projections "conservative."